Turkish Journal of Biology
Volume 40

Number 4

Article 10

1-1-2016

Potential therapeutic effects of silymarin and silymarin-loaded
solid lipidnanoparticles on experimental kidney damage in
BALB/c mice: biochemical and histopathological evaluation
MUSTAFA CENGİZ
ADNAN AYHANCİ
HATİCE MEHTAP KUTLU
AHMET MUSMUL

Follow this and additional works at: https://journals.tubitak.gov.tr/biology
Part of the Biology Commons

Recommended Citation
CENGİZ, MUSTAFA; AYHANCİ, ADNAN; KUTLU, HATİCE MEHTAP; and MUSMUL, AHMET (2016) "Potential
therapeutic effects of silymarin and silymarin-loaded solid lipidnanoparticles on experimental kidney
damage in BALB/c mice: biochemical and histopathological evaluation," Turkish Journal of Biology: Vol.
40: No. 4, Article 10. https://doi.org/10.3906/biy-1506-75
Available at: https://journals.tubitak.gov.tr/biology/vol40/iss4/10

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Biology by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Biology

Turk J Biol
(2016) 40: 807-814
© TÜBİTAK
doi:10.3906/biy-1506-75

http://journals.tubitak.gov.tr/biology/

Research Article

Potential therapeutic effects of silymarin and silymarin-loaded solid lipid
nanoparticles on experimental kidney damage in BALB/c mice: biochemical and
histopathological evaluation
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Abstract: Silymarin (Sm) is widely used in treating diseases that affect organs such as the liver, kidney, and gallbladder thanks to its
antioxidative, renoprotective, antihepatotoxic, and anticarcinogenic properties. However, this substance is poorly solved in water and
tends to decompose in the intestine, its bioavailability decreasing before it can show real effect. With these limitations in mind, the
present study aims to enhance the poor bioavailability of Sm by forming Sm-loaded solid lipid nanoparticles (Sm-SLNs) using the
hot homogenization method. A characterization process was undertaken to determine possible impact of Sm on experimental kidney
damage. Our biochemical and light microscopic results suggest that the group that received Sm-SLNs for the treatment of D-GalN/
TNF-α–induced experimental kidney damage showed significantly more improvement than the group that received commercially
available Sm. In conclusion, Sm-loaded SLN may be a useful system for the delivery of poorly water-soluble Sm and may also provide
renoprotection.
Key words: D-GalN/TNF-α, kidney damage, silymarin, solid lipid nanoparticle, renoprotectivity

1. Introduction
Renal dysfunction is a common and serious problem
associated with advanced stages of liver disease. Renal
failure is widely known to occur spontaneously in most
patients suffering from acute liver failure (Ring-Larsen
and Palazzo, 1981). Hepatotoxic substances including
acetaminophen (Pritchard and Butler, 1989; Bourdi et al.,
2002), carbon tetrachloride (CCl4), lipopolysaccharides
(Shi et al., 1998; Morio et al., 2001), D-galactosamine
(D-GalN), and tumor necrosis factor alpha (TNF-α)
are extensively employed in treating experimentally
induced acute liver damage cases (Bradham et al., 1998).
Administration of D-GalN/TNF-α in varying doses
to induce liver injury is a widely chosen experimental
method, and it is used for examining pathogenesis of
the liver tissue (Tapalaga et al., 2002). TNF-α is not just
a cytokine produced and released in macrophages; it is
also released at lower intensity by lymphocytes, mast cells,
endothelial cells, fibroblasts, and nerve cells (Bradham
et al., 1998). D-GalN is a specific hepatotoxic agent,
and it blocks hepatic mRNA transcription by depleting
* Correspondence: hmkutlu@anadolu.edu.tr

uridine nucleotides metabolically (Leist et al., 1994).
Although the effects of sole D-GalN (Sracyn et al., 2004)
or TNF-α (Tracey et al., 1986) applications on the kidney
can be observed, it remains to be seen what influence a
combination of D-GalN and TNF-α exerts upon on this
tissue.
Sm has generated promising hepatoprotective effects,
not only experimentally but also clinically. Antioxidant
and anti-inflammatory properties of Sm may also act as
a protective agent against photocarcinogens (Mudit and
Santosh, 2010) and nephropathic processes (Kren and
Walterová, 2005). Administration of silibin, the major
active constituent of silymarin, before and after chemically
induced injury has been shown to prevent or reduce
nephrotoxic effects. Therefore, it was assumed that Sm
may act as a renoprotective agent against nephrotoxic
medications (Sonnenbichler et al., 1999). The protective
effects of Sm on drug-induced nephrotoxicity have
been observed, mainly in experiments done on animals,
and renoprotection against cisplatin is most frequently
reported. However, due to its poor ability to dissolve in
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water, bioavailability of Sm is rather low (Lorenz et al., 1997;
Provinciali et al., 2007). According to pharmacokinetic
investigations, only 23%–47% of Sm manages to reach
systemic circulation once it has been taken orally (Lorenz
et al., 1984; Schulz et al., 1995).
In the present study, Sm-loaded solid lipid
nanoparticles (Sm-SLNs) were prepared using the hot
homogenization method so that a new kind of Sm-loaded
SLN with enhanced bioavailability could be obtained.
Herein, renoprotective activities of synthesized Sm-loaded
SLN and commercial Sm in D-GalN/TNF-α–induced
kidney damage on BALB/c mice were investigated.
2. Materials and methods
2.1. Chemicals
Sm was provided by Sigma Aldrich (St. Louis, MO, USA).
Compritol and polyoxyethylene sorbitan monooleate
(Tween 80) were obtained from Merck Schuchardt
(Darmstadt, Germany). Tumor necrosis factor-alpha
(human recombinant E. coli) and D-galactosamine were
supplied by Gattefosse (Saint-Priest Cedex, France),
Duksan Chemical Company (Ansan, South Korea), Calbio
Chem and Acros Organics, respectively.
2.2. Animals
In this study, 10-week-old BALB/c male mice (n = 35)
weighing 20–25 g were used. The mice were kept under
controlled laboratory conditions and were sustained
with pellets and tap water. The animals were randomly
categorized into 5 groups, each containing 7 mice. They
were kept in daylight and dark for 12 h at 22 ± 2 °C and
45%–50% humidity in automated controlled rooms. All
procedures concerning the animals in this study were
approved by the Anadolu University Animal Welfare
Committee.
2.3. Experimental design
The mice were placed in five groups, each containing seven.
Group 1 received 0.5 mL of saline i.p. Group 2 received
only D-GalN/TNF-α, i.p; group 3 received Sm 4 h after
being given i.p. D-GalN/TNF-α; group 4 received Sm-free
SLN 4 h after being given D-GalN/TNF-α, i.p; and group

5 received Sm-SLNs 4 h after being given D-GalN/TNF-α,
i.p. Groups 1 and 2 were sacrificed 4 h after the injection
procedure (Gezginci-Oktayoglu et al., 2008), while the
others were sacrificed 24 h after the final injections
(Muriel and Mourelle, 1990). TNF-α was administered
to each of the mice once it had been dissolved in distilled
water in doses of 15 µg/kg. However, Sm was solved in
harmless doses of dimethyl sulfoxide (DMSO), and then
water was added to this mixture before it was injected
to the experimental animals. D-GalN was administrated
in doses of 700 mg/kg after being dissolved in distilled
water. Finally, 100 mg/kg Sm, which had been dissolved in
distilled water, was injected into the mice along with 100
mg/kg Sm-free SLN and Sm-loaded SLN, which had been
prepared in solution form (Table 1).
2.4. Biochemical assays
Serums were obtained from the blood samples of the mice
used in the experiment for 10 min at 3000 rpm. The samples
were then analyzed to determine serum glutathione (GSH)
blood urea nitrogen (BUN), creatinine (Cre), and plasma
malondialdehyde (MDA) with the help of an automated
biochemical auto-analyzer (HITACHI-917).
2.5. Preparation of Sm-loaded SLNs
SLNs were prepared with the hot homogenization
technique, as reported by Muller et al. (2000). Lipid matrix
was melted at about 80 °C, and a certain amount of Sm
was then added. After distillation, water with surfactants
(Tween 80) was heated until the same temperature was
achieved. The hot lipid phase was poured over the hot
water–surfactants solution using an Ultra-Turrax at
20,500 rpm (T25, Janke & Kunkel IKA, Germany), and
this was cooled at room temperature so that solid lipid
nanosuspension could be obtained.
2.6. Characterization of SLNs
The average diameters (particle size) and polydispersity
index (PI) of SLNs were determined with the aid of photon
correlation spectroscopy (PCS) using a Nano Zetasizer (ZS,
Malvern, UK) at a fixed angle of 90° and at a temperature
of 25 °C. The PI is a measure of the size distribution of
a nanoparticle population. Before colloidal dispersion

Table 1. Names of the experimental groups, chemicals administered, and doses.
Hours
Group name

808

0

4

Group 1 (control)

Saline (0.5 mL)

Sacrificed

Group 2

700 mg/kg D-GalN /15 µg/kg TNF-α

Sacrificed

28

Group 3

700 mg/kg D-GalN /15 µg/kg TNF-α

100 mg/kg Sm

Sacrificed

Group 4

700 mg/kg D-GalN /15 µg/kg TNF-α

100 mg/kg Sm-free SLN

Sacrificed

Group 5

700 mg/kg D-GalN /15 µg/kg TNF-α

100 mg/kg Sm-loaded SLN

Sacrificed
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stability could be assessed, the zeta potential was measured
with a Nano Zetasizer at 25 °C. SLNs were then suspended
in distilled water (pH 7). All the samples were analyzed
in triplicate. Sm-loaded SLNs were also characterized
by transmission electron microscopy (TEM) (TEM FEI
Tecnai BioTWIN). The SLNs were spread over a Cu grid
and then stained with uranyl acetate for observation by
TEM. The zeta potential of the particles was determined
by Malvern Zetasizer Nano ZS (Malvern Instruments). In
order to determine Stern potential, some measurements
were performed in bidistilled water adjusted with a 0.9%
(w/v) sodium chloride solution to a conductivity of 50 µS/
cm.
2.7. Histopathological investigations
The kidney tissues harvested from the mice were cut
into small pieces and fixed in Bouin’s solution. Following
dehydration in an ascending ethanol series (70%, 90%,
96%, 100%), the tissue samples were cleared in xylene,
embedded in paraffin, and sliced in 5–6 m sections, which
were then stained with hematoxylin–eosin (H-E) and
Masson’s trichrome (Masson), thus exposing collagen.
2.8. Statistical analysis
SPSS 12.0 for Windows was used to assess the data obtained
in this study. The numerical value (P) for the difference
was significant at P < 0.05.
3. Results
3.1. Particle size and zeta potential
To date, SLNs have been prepared with diverse methods
that play a crucial part in the particle size, shape,
controlled drug release, entrapment efficacy, and stability
of SLNs (Koppel, 1972). Particle size is one of the most
significant physical properties of colloidal carrier systems
when determining physical stability and activity of SLNs
(Numanoğlu and Tarımcı, 2006). In the present study, Sm
particle sizes changed from 600 nm to nearly 5 µm, while
Sm-loaded SLN particle sizes varied between 165 and
200 nm (Table 2). Tween 80 also maintained the stability
of SLN (Demirel et al., 2001). Furthermore, SEM images
showed that particle size of SLN formulations was smaller
than those of Sm, and that Sm had a cubic shape while

SLN formulations were circular (Figure 1). Based on these
results, it was concluded that SLN formulation reduced the
particle size of Sm, which can be observed in Table 2. Our
results are consistent with those in the literature (Takka et
al., 2005). Predictions about the storage stability of colloidal
dispersion were achieved by determining zeta potential. In
this study, all the formulations were negatively charged
and changed from −21.2 to −25.9 m V. Sm-loaded SLNs
showed relatively good physical stability and dispersion
quality (Venkateswarlu and Manjunath, 2004). The zeta
potential value could be affected by aggregation and
storage conditions. However, particle aggregation is less
likely to occur for charged particles (high zeta potential)
due to electric repulsion (Al-Haj and Rasedee, 2009). Zeta
potential values of Sm-loaded SLNs are shown in Table 2.
3.2. Histological results
Hematoxylin-eosin–stained samples were scrutinized
under light microscopy. The structure of the kidney tissues
was normal in the control group (group 1). However,
kidney structures of the mice given D-GalN/TNF-α
(group 2) and D-GalN/TNF-α/Sm-free SLN (group 4)
were severely impaired. Based upon the tissue samples,
it was determined that the kidneys of the mice had been
damaged because there was extensive tubular damage and
cellular infiltration in the interstitial region of the kidney
cortex, as well as vascular congestion (Figure 2). The kidney
samples of group 3 (Figure 2) and group 5 revealed that the
kidneys of the mice in group 5 were better protected than
those in group 3. Furthermore, the results of group 5 were
remarkably similar to those of the control group (Figure 2).
3.3. Biochemical results
D-GalN/TNF-α (group 2) and D-GalN/TNF-α/Sm-free
SLN (group 4) administration increased serum BUN
and Cre levels significantly. Sm and Sm-loaded SLN
significantly decreased serum BUN and Cre levels after
D-GalN/TNF-α administration (P < 0.05) (Figures 3
and 4). A comparison of serum GSH and plasma MDA
levels in group 2 with those of the control group showed
a significant decrease in GSH levels, while plasma MDA
levels increased dramatically (P < 0.001). In group 3, serum
GSH levels increased, but plasma MDA levels decreased

Table 2. The particle size, zeta potential, and polydispersity index of Sm, Sm-loaded SLNs, and Sm-free SLNs. Data
are presented as mean values and show standard deviation (n = 3).
Particle size (nm)
Formulations

Mean (n = 3)

S.D.

Polydispersity index (PI)

Zeta potential (mV)

Mean (n = 3)

Mean (n = 3)

S.D.

S.D

Sm

5000

1.3024

0.562

0.01

-

-

Sm-free SLN

200

1.2087

0.451

0.03

–25

0.007

Sm-loaded SLN

165

0.5247

0.401

0.02

–26.5

0.005
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Figure 1. SEM images. Sm (A) and Sm-SLN (B).

when compared to those of group 2 (P < 0.001). As for
group 4, there was a difference between serum GSH and
plasma MDA levels in groups 4 and 2, but this difference
did not achieve statistical significance (P > 0.05). In group
5, serum GSH levels increased significantly as opposed to
plasma MDA levels, which decreased significantly when
compared to those in groups 2 and 4 (P < 0.001). On the
other hand, differences in MDA and GSH levels between
groups 3 and 5 had no statistical significance (P > 0.05).
4. Discussion
The present study investigates whether Sm-loaded SLN
treatment can prevent the development of D-GalN/
TNF-α–induced cardio toxicity. Our histological results
show the kidney specimens harvested from mice 4 h
after they had been given 700 mg/kg D-GalN and 15 µg/
kg TNF-α (group 2) and 700 mg/kg D-GalN/15 µg/kg
TNF-α/100 mg/kg SLN (group 4). In the same vein, BUN
and Cre levels increased (Figures 3 and 4). In addition,
plasma MDA levels increased significantly (Table 3) when
compared to those of the control group, while serum GSH
levels decreased remarkably (P < 0.001). Our histological
and biochemical findings were consistent with those in the
literature.
Anand et al. (2002) showed that treatment with
D-GalN results in renal failure, which is manifested by a
decrease in renal blood flow, creatinine clearance along
with a rise in plasma endothelin-1 (ET-1) concentration,
and the upregulation of ET-1 receptor in the renal cortex.
This study also suggests that renal failure may develop
secondary to severe liver damage. Likewise, GalN
administration at a dose of 800 mg/kg for three consecutive
days caused enhanced oxidative insult in the kidney tissue,
as demonstrated by the increased renal malondialdehyde
(MDA) levels and reduction in the activity of endogenous
antioxidant enzymes, such as GSH. GalN intoxication also
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reduced the levels of total thiol and glutathione followed
by an increase in oxide glutathione (GSSG) levels. Renal
dysfunction due to GalN treatment was also manifested
by an increase in serum Cre and urea nitrogen (UN) levels
as, compared to the untreated mice (Sinha et al., 2007).
Another study reported the D-GalN/TNF-α combination
triggers kidney injury, which appears to be secondary to
liver injury (Gezginci-Oktayoglu et al., 2008). Gezginci et
al. (2008) studied kidney damage caused by a combination
of 700 mg/kg D-GalN and 15 µg/kg TNF-α and observed
tubular injury, less prominent glomerular injury,
shortening at the brush border, and mononuclear cell
infiltration 4 h subsequent to D-GalN/TNF-α injection.
Moreover, treatment with D-GalN/TNF-α significantly
decreased the GSH levels (29.14 ± 4.66 vs. 18.23 ± 1.43).
Cre, an indicator of glomerular function of the kidney, and
BUN are also employed as indicators in determining the
extent of the damage to kidney tissue. Serum creatinine
and BUN levels have been reported to increase once the
kidney has received damage (Senthilkumar et al., 2006).
The present study also found extensive tubular
damage, intensive cell infiltration, and vascular congestion
in the kidney cortex, all of which were induced by 700
mg/kg D-GalN and 15 µg/kg TNF-α. Liver tissue damage
was reduced in the groups given Sm and Sm-loaded
SLN. Likewise, the rise in MDA, BUN, and Cre levels
due to kidney damage reversed, and serum GSH levels
increased remarkably (P < 0.001). However, Sm-loaded
SLN has proved to be a more effective alternative than
Sm thanks to its superior performance in healing kidney
damage (Figure 2). In one study following renal I/R injury,
significant tubular dilatation, tubular vacuolization,
pelvic inflammation, interstitial inflammation, perirenal
adipose infiltration, tubular necrosis, and glomerular
necrosis (cortical necrosis) were observed. Nevertheless,
histopathological changes due to I/R injury were

CENGİZ et al. / Turk J Biol

Group 2

Group 3

Group 4

Group 5

Figure 2. Kidney with normal histological structures (group 1); kidney structures extensively damaged by D-GalN/TNF-α (group
2); [extensive cellular infiltration in the interstitial region of the kidney cortex (*) and vascular congestion (→)]; partial recovery due
to Sm in kidney damaged by D-GalN/TNF-α (group 3); [narrowing in the space of Bowman in Malpighian corpuscles of the kidney
cortex (→) and some vascular congestion (►)]; kidney with histological structures damaged by D-GalN/TNF-α given prior to Smfree SLN (group 4) injection; remarkable recovery due to Sm-loaded SLN in the kidney damaged by D-GalN/ TNF-α (group 5).
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Figure 3. Effect of D-GalN/TNF-α, Sm, Sm-free SLN, and Sm-loaded SLN on the activities of
BUN in kidney. All values are the mean ± SD (n = 7). aP < 0.001 compared to control, bP < 0.001
compared to group 2, cP < 0.001 compared to group 3, dP < 0.001 compared to group 4.

Figure 4. Effect of D-GalN/TNF-α, Sm, Sm-Free SLN, and Sm-loaded SLN on the activities of
Cre in kidney. All values are the mean ± SD (n = 7). aP < 0.001 compared to control, bP < 0.001
compared to group 2, cP< 0.001 compared to group 3, dP < 0.001 compared to group 4.

prevented, even with a low dose of 100 mg/kg Sm (Senturk
et al., 2008). Thus, our findings appear to be in line with
those published in the literature. In one study 50 mg/kg
Sm was provided to rats in order to cure them of 3 mg/
kg cisplatin-induced kidney damage, and Sm prevented
BUN and creatinine from increasing (Karimi et al., 2005).
In another study, a single dose of adriamycin (10 mg/
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kg) produced proximal tubular degeneration and cast
formation, which characterized nephrotoxicity, and a
posttreatment of 50 mg/kg Sm showed protection against
ADR-induced nephrotoxicity (El-Shitany et al., 2008). Sm
also normalized ADR-induced increases in kidney MDA
and restored the depleted GSH contents (Mansour et al.,
2006).
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Table 3. Serum GSH and plasma MDA levels of blood samples taken from BALB/c mice.
Groups

GSH (nmol/mg protein)

MDA (nmol/mg protein)

Group 1 (control)

31.4 ± 2.15

0.31 ± 0.03

Group 2

5.16 ± 0.33 ***

1.38 ± 0.11***

Group 3

18 ± 0.8 *** ###

Group 4

5.08 ± 0.35 ***

Group 5

27.43 ± 3.11**### ΔΔΔ @@@

0.74 ± 0.06*** ###
1.39 ± 0.11*** ΔΔΔ

ΔΔΔ

0.39 ± 0.04### ΔΔΔ @@@

All values are the mean ± SD (n = 7). Statistical significance between means was performed
using one-way analysis of variance (ANOVA) followed by Tukey–Kramer as a post-ANOVA
test (P < 0.05). Means with the same letter within the same parameter are not significantly
different. **P < 0.05 compared to control, ***P < 0.001 compared to control, ### P < 0.001
compared to group 2, ΔΔΔ P < 0.001 compared to group 3, @@@ P < 0.001 compared to group 4.

In conclusion, Sm-loaded SLN was found to be more
effective in curing kidney damage than Sm, which can
be attributed to the slow and regular release of Sm by
nanoparticles providing Sm with a rise in bioavailability,
which, in turn, improves its therapeutic effects.
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